How much is enough and who says so? The case of the King's Health Questionnaire and overactive bladder

被引:121
作者
Kelleher, CJ
Pleil, AM
Reese, PR
Burgess, SM
Brodish, PH
机构
[1] Pfizer La Jolla, Worldwide Outcomes Res, San Diego, CA 92121 USA
[2] Guys & St Thomas Hosp, London SE1 9RT, England
[3] Reese Associates Consulting LLC, Cary, NC USA
[4] CareScience, Res Triangle Pk, NC USA
关键词
D O I
10.1111/j.1471-0528.2004.00129.x
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Background One of the challenges of health-related quality of life research is to translate statistically significant health-related quality of life changes into interpretable clinical or medically important ones. Objective To calculate the minimal important difference of the King's Health Questionnaire, a condition-specific health-related quality of life questionnaire for the assessment of men and women with lower urinary tract dysfunction. Methods The King's Health Questionnaire was administered to patients suffering from overactive bladder enrolled in two multinational studies. Minimal important differences were calculated using an anchor-based approach with both a global rating of patient-perceived treatment benefit and one of perceived disease impact. A distribution-based method using effect size was calculated for comparison purposes. Results Minimal important difference values varied slightly with each method. Using the anchor-based approach, the King's Health Questionnaire minimal important difference ranged between 5-10 points when the calculation factored out patients who reported no change and 6-12 points for patients who experienced a small improvement. The effect size method indicated a minimal important difference of 5 to 6 points for a small effect and 10 to 15 points for a medium effect. Conclusions In the case of the King's Health Questionnaire, the anchor-based approaches and the distribution-based approach provide similar results. A change from baseline of at least 5 points on King's Health Questionnaire domains indicates a change that is meaningful to patients and is indicative of a clinically meaningful improvement in health-related quality of life after treatment. Convergence of the estimates using different approaches should give us confidence in the values derived for the quality of life domains measured by the King's Health Questionnaire.
引用
收藏
页码:605 / 612
页数:8
相关论文
共 33 条
[1]   Impact of the global on patient perceivable change in an asthma specific QOL questionnaire [J].
Barber, BL ;
Santanello, NC ;
Epstein, RS .
QUALITY OF LIFE RESEARCH, 1996, 5 (01) :117-122
[2]   Tolterodine, an effective and well tolerated treatment for urge incontinence and other overactive bladder symptoms [J].
Chancellor, M ;
Freedman, S ;
Mitcheson, HD ;
Antoci, J ;
Primus, G ;
Wein, A .
CLINICAL DRUG INVESTIGATION, 2000, 19 (02) :83-91
[3]  
Cohen J, 1998, STAT POWER ANAL BEHA
[4]  
CROSBY RD, 2001, VALUE HEALTH, V4, P177
[5]   Methods to explain the clinical significance of health status measures [J].
Guyatt, GH ;
Osoba, D ;
Wu, AW ;
Wyrwich, KW ;
Norman, GR .
MAYO CLINIC PROCEEDINGS, 2002, 77 (04) :371-383
[6]   The concept of clinically meaningful difference in health-related quality-of-life research - How meaningful is it? [J].
Hays, RD ;
Woolley, JM .
PHARMACOECONOMICS, 2000, 18 (05) :419-423
[7]   CLINICAL-SIGNIFICANCE - A STATISTICAL APPROACH TO DEFINING MEANINGFUL CHANGE IN PSYCHOTHERAPY-RESEARCH [J].
JACOBSON, NS ;
TRUAX, P .
JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY, 1991, 59 (01) :12-19
[8]   MEASUREMENT OF HEALTH-STATUS - ASCERTAINING THE MINIMAL CLINICALLY IMPORTANT DIFFERENCE [J].
JAESCHKE, R ;
SINGER, J ;
GUYATT, GH .
CONTROLLED CLINICAL TRIALS, 1989, 10 (04) :407-415
[9]   INTERPRETING CHANGES IN QUALITY-OF-LIFE SCORE IN N OF 1 RANDOMIZED TRIALS [J].
JAESCHKE, R ;
GUYATT, GH ;
KELLER, J ;
SINGER, J .
CONTROLLED CLINICAL TRIALS, 1991, 12 (04) :S226-S233
[10]   Quality of life questionnaires: Does statistically significant = clinically important? [J].
Juniper, EF .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1998, 102 (01) :16-17